dabigatran has been researched along with No-Reflow Phenomenon in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Ma, C; Sheng, J; Song, K; Wang, Y | 1 |
| Hale, SL; Kloner, RA | 1 |
2 other study(ies) available for dabigatran and No-Reflow Phenomenon
| Article | Year |
|---|---|
Effects of dabigatran regulates no‑reflow phenomenon in acute myocardial infarction mice through anti‑inflammatory and anti‑oxidative activities and connective tissue growth factor expression.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Pressure; Connective Tissue Growth Factor; Dabigatran; Gene Expression; Mice; Myocardial Infarction; No-Reflow Phenomenon; Oxidative Stress; Rabbits; Transforming Growth Factor beta1 | 2018 |
Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Male; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Rabbits | 2015 |